Clinical trials
Schedule appointment
(352) 294-5000
-
The Stronger Study -
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an…
- Investigator
- Nicole M Iovine
- Ages
- 18 Years - N/A
- Sexes
- All
-
Using a New Drug Nivolumab in Combination with Chemotherapy to Treat Nasopharyngeal Carcinoma (NPC) This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune…
- Investigator
- Brian Stover
- Ages
- N/A - 21 Years
- Sexes
- All
-
Levocarnitine To Protect the Liver From Chemotherapy for Leukemia or Lymphoma This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care…
- Investigator
- Brian Stover
- Ages
- 15 Years - 40 Years
- Sexes
- All
-
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving…
- Investigator
- Brian Stover
- Ages
- 4 Years - 17 Years
- Sexes
- All
-
ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for High-Risk NBL This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with…
- Investigator
- Brian Stover
- Ages
- N/A - 30 Years
- Sexes
- All
-
A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell H This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after…
- Investigator
- Brian Stover
- Ages
- 180 Days - 22 Years
- Sexes
- All
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other…
- Investigators
- Brian Stover, William Slayton
- Ages
- 3 Years - 29 Years
- Sexes
- All
-
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in P This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common…
- Investigators
- Brian Stover, William Slayton
- Ages
- 2 Years - 25 Years
- Sexes
- All
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Ne Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using…
- Investigators
- Brian Stover, William Slayton
- Ages
- N/A - 21 Years
- Sexes
- All